Athersys Stock News

Athersys to Host Year-End 2021 Financial Results Call; New CEO, Daniel A. Camardo, and Management to Host Conference Call on March 15, 2022

Athersys Inc. (NASDAQ:ATHX) price on Thursday, February 10, rose 0.78% above its previous days close as an upside momentum from buyers pushed the stocks value to $0.97. A look at the stocks price movement, the close in the last trading session was $0.96, moving within a range at $0.925 and $1.03. The beta value (5-Year Athersys Inc.s (NASDAQ:ATHX) Stock Price Rises 7.74% This Year: A Look At Likely Future Paths Read More »

Penny stocks under $1 The post 5 Top Penny Stocks To Buy Under $1 On Webull According To Reddit appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Athersys (ATHX) appoints Daniel A. Camardo as the company''s CEO, effective February 14, 2022.Mr

Company has a robust pipeline in late-stage clinical development largely unknown to investors.

Athersys Inc (ATHX) shares closed 0.3% lower than its previous 52 week low, giving the company a market cap of $232M. The stock is currently down 43.6% year-to-date, down 47.5% over the past 12 months, and down 38.3% over the past five years. This week, the Dow Jones Industrial Average rose 3.9%, and the S&P 500 rose 4.9%. Trading Activity Trading volume this week was 25.2% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.6. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -254.3% The company's stock price performance over the past 12 months lags the peer average by -273.6% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Athersys Inc. (NASDAQ:ATHX) traded at $0.98 at close of the session on Tuesday, 12/21/21, made a downward move of -1.59% on its previous days price. Looking at the stock we see that its previous close was $1.00 and the beta (5Y monthly) reads -1.58 with the days price range being $0.9663 $1.01. In terms Athersys Inc.s Stock Price Soared Recently, But There Might Be Trouble Ahead Read More »

Analysts expect that Athersys, Inc. (NASDAQ:ATHX) will post earnings of ($0.07) per share for the current quarter, according to Zacks. Zero analysts have provided estimates for Athersys earnings. The lowest EPS estimate is ($0.09) and the highest is ($0.05). Athersys reported earnings of ($0.11) per share during the same quarter last year, which suggests a []

Athersys, Inc. (NASDAQ:ATHX) with the stream of 4.00% also noticed, India ECMOHO Limited (NASDAQ:MOHO) encountered a rapid change of -0.30% in the last hour of Wednesdays trading session. Athersys, Inc. The post Bustling Stock: Athersys, Inc. (NASDAQ:ATHX), ECMOHO Limited (NASDAQ:MOHO) appeared first on Stocks Equity .

Sequoia Financial Advisors LLC raised its position in Athersys, Inc. (NASDAQ:ATHX) by 28.4% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 181,000 shares of the biopharmaceutical company’s stock after acquiring an additional 40,000 shares during the period. Sequoia Financial Advisors LLC owned approximately 0.08% of Athersys worth […]

Zacks Investment Research downgraded shares of Athersys (NASDAQ:ATHX) from a buy rating to a hold rating in a report issued on Thursday morning, Zacks.com reports. According to Zacks, Athersys, Inc., a late stage biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused primarily []

Zacks Investment Research cut shares of Athersys (NASDAQ:ATHX) from a buy rating to a hold rating in a research note issued to investors on Thursday morning, Zacks.com reports. According to Zacks, Athersys, Inc., a late stage biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs []

Millennium Management LLC bought a new position in shares of Athersys, Inc. (NASDAQ:ATHX) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 1,002,826 shares of the biopharmaceutical companys stock, valued at approximately $1,444,000. Millennium Management LLC owned approximately 0.44% of Athersys as of []

In the latest trading session, 0.61 million Athersys Inc. (NASDAQ:ATHX) shares changed hands as the companys beta touched -1.57. With the companys most recent per share price at $1.07 changing hands around $0.05 or 4.41% at last look, the market valuation stands at $253.91M. ATHXs current price is a discount, trading about -183.18% off its Athersys Inc. (ATHX): Why Is Stock So Good? Read More »